Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Media

Oncology Nursing News Logo

Ready-to-Dilute Thiotepa Approved for Breast and Ovarian Adenocarcinomas

May 16th 2025April 30th 2025

Read More

Cure Today Logo

FDA Approves Ready-to-Dilute Tepylute for Breast and Ovarian cancer

May 16th 2025April 30th 2025

Read More

The Pharma Letter Logo

Shorla wins FDA nod for ready-to-dilute Tepylute

May 16th 2025April 29th 2025

Read More

MPR LOGO

Tepylute, a Ready-to-Dilute Formulation of Thiotepa, Now Available

May 16th 2025April 29th 2025

Read More

FDA Approval and U.S. Launch of Tepylute® 15 MG AND 100 MG

June 23rd 2025April 29th 2025

Read More

Bussiness Awards 2024

Sharon and Orlaith were recently awarded the Irish Times Future Leaders award

February 24th 2025

Read More

Shorla Oncology

Shorla Oncology develops and commercializes innovative oncology drugs, where existing treatments are limited, in shortage or inadequate.

April 29th 2025November 26th 2024

Read More

Logo

Shorla, Protega Win Expanded Nods for Cancer/Autoimmune, Pain Therapies

November 8th 2024November 1st 2024

Read More

FDA

FDA expands Jylamvo approval to include polyarticular juvenile idiopathic arthritis, ALL

February 20th 2025November 1st 2024

Read More

Older posts
Newer posts
Page1 Page2 Page3 … Page7
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

CALIFORNIA COMPLIANCE PROGRAM DECLARATION

Company number: 618033
©SHORLA ONCOLOGY® 2025

© 2025 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.